Tiffany Tanaka - Concepedia

Author

Tiffany Tanaka

University of California San Diego ORCID

Also Known As

T Tanaka, T. Tanaka, Tiffany N Tanaka, Tiffany N. Tanaka, Tiffany Tanaka

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego Moffitt Cancer Center City Of Hope National Medical Center Roswell Park Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center

About

Tiffany Tanaka is an author at University of California San Diego specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	245
2	Immunology	4	4	209
3	Health Sciences	1	1	18
4	Cell Biology	1	1	93
5	Molecular Medicine	1	1	18

Tiffany Tanaka

Publications

856

Citations

H-Index

Page 1

	Year	Citations
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Journal of Clinical Oncology	2023	148
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update Julia Bohlius, Kari Bohlke, Roberto Castelli, Journal of Clinical Oncology	2019	136
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results Naval Daver, Paresh Vyas, Suman Kambhampati, Journal of Clinical Oncology	2023	110
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology Neil P. Shah, Ravi Bhatia, Jessica K. Altman, Journal of the National Comprehensive Cancer Network	2024	96
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages Isidoro Cobo, Tiffany Tanaka, Kailash Chandra Mangalhara, Immunity InflammationMitochondrial BiogenesisMitochondrial FunctionImmunologyCell Death	2022	93
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results David A. Sallman, Adam Asch, Suman Kambhampati, Clinical Lymphoma Myeloma & Leukemia Phase 1BOncologyImmunologyAml PatientsImmune Checkpoint Inhibitor	2021	51
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. Naval Daver, Paresh Vyas, Suman Kambhampati, Journal of Clinical Oncology Phase 1BHematological MalignancyOncologyAcute Myeloid LeukemiaMetronomic Therapy	2022	47
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes Brian M. Reilly, Tiffany Tanaka, Dinh Diep, Blood Advances	2019	41
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia Bruno C. Medeiros, Tiffany Tanaka, Larisa Balaian, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyOncologyGemtuzumab OzogamicinMedicineAcute Myeloid Leukemia	2018	36
Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Isidoro Cobo, Tiffany Tanaka, Christopher K. Glass, PubMed	2022	30

Page 1